Merck Annual Report 2011 - Overview compounds (optimized for printing)

Status of our innovative compounds

1	Collaboration between Merck KGaA, Darmstadt, Germany, and ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. Erbitux® is a trademark of ImClone, used under license by Merck
2	Study sponsored and coordinated by the Fédération Francophone de Cancérologie Digestive (FFCD)
3	Exclusive worldwide licensing rights acquired from Oncothyreon Inc.
4	Combined with PI3K/mTOR inhibitor (SAR245409), conducted by Merck, or combined with PI3K inhibitor (SAR245408), conducted by sanofi-aventis U.S. Inc.
5	Scientific collaboration with M. D. Anderson Cancer Center
6	Sponsored by the National Cancer Institute (NCI), USA
7	Collaboration with Apitope Technology (Bristol) Ltd.
8	Collaboration with Flamel Technologies S.A.
9	In-licensed from ZymoGenetics, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb Company
10	Phase IIIb study as part of the EMA’s requirements for registration
NSCLC: Non-small cell lung cancer
SCCHN: Squamous cell carcinoma of the head and neck
mCRC: Metastatic colorectal cancer
mCRPC: Metastatic castration-resistant prostate cancer
S1P: Sphingosin-1 phosphate
PKU: Phenylketonuria

Therapeutic area

Compound

Indication

Status

Oncology

Non-small cell lung cancer (NSCLC)

EU: filed

Adjuvant colorectal cancer²

Phase III

Erbitux® (cetuximab, anti-EGFR monoclonal antibody)¹

Gastric cancer

Phase III

Cilengitide (integrin inhibitor)

Glioblastoma (brain tumor)

Phase III

Stimuvax® (cancer immunotherapy)³

Non-small cell lung cancer (NSCLC)

Phase III

Head and neck cancer (SCCHN)

Phase II

Cilengitide

Non-small cell lung cancer (NSCLC)

Phase II

Metastatic colorectal cancer (mCRC)

Phase II

Anti-integrin monoclonal antibody (DI17E6)

Metastatic prostate cancer (mCRPC)

Phase II

Pimasertib (AS703026/MSC1936369B, MEK inhibitor)

Solid tumors and hematological malignancies

Phase I

Novel combinations of pimasertib with one of two PI3K inhibitors from sanofi-aventis U.S. Inc.⁴

Solid tumors

Phase I

MEK inhibitor (AS703988/MSC2015103B)

Solid tumors

Phase I

c-Met kinase inhibitor (EMD1214063)⁵

Solid tumors

Phase I

NHS-IL12 (cancer immunotherapy)⁶

Solid tumors

Phase I

Multiple Sclerosis

Human serum albumin-free formulation of Rebif®

Treatment of patients with early signs of MS

EU: approved

ONO-4641
(oral S1P receptor modulator)

Phase II

ARX 424 (long-acting interferon)

Phase I

ATX-MS-1467
(immune tolerance therapy)⁷

Phase I

Extended-release formulation of interferon beta-1a⁸

Phase I

Plovamer (PI-2301, second-generation peptide copolymer)

Phase I

DI Fc-IFN beta variant (long-acting interferon)

Phase I

Rheumatology

Atacicept (anti-BLyS/anti-APRIL fusion protein)⁹

Systemic lupus erythematosus (SLE)

Phase II

Cartilage injury

Phase II

Fibroblast growth factor (FGF) 18⁹

Osteoarthritis

Phase I

Endocrinology

Kuvan® (sapropterin)

PKU in children under the age of 4¹⁰

Phase III